RhumbLine Advisers’s Generate Biomedicines GENB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$444K Sell
29,562
-1,086
-4% -$16.7K ﹤0.01% 2808
2026
Q2
$517K Buy
+30,648
New +$418K ﹤0.01% 2747

Other funds holding GENB

RhumbLine Advisers's GENB Position: Q3 2026 in Review

RhumbLine Advisers reduced its Generate Biomedicines (GENB) stake by 3.5% in Q3 2026, selling an estimated $16.7K and leaving 29,562 shares worth $444K. The position accounts for ﹤0.01% of the portfolio, ranked #2808.

RhumbLine Advisers first reported a position in GENB in Q2 2026 and has held it in 2 quarters since. The position peaked at $517K in Q2 2026. 109 funds tracked by Wall St. Rank hold GENB as of Q3 2026.

  • RhumbLine Advisers held 29,562 shares of Generate Biomedicines worth $444K as of Q3 2026.
  • RhumbLine Advisers sold 1,086 Generate Biomedicines shares in Q3 2026, an estimated $16.7K.
  • Generate Biomedicines made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #2808 holding.
  • RhumbLine Advisers first reported a position in Generate Biomedicines in Q2 2026 and has held it in 2 quarters since.
  • RhumbLine Advisers's Generate Biomedicines position peaked at $517K in Q2 2026.
  • 109 funds tracked by Wall St. Rank held Generate Biomedicines as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.